DISC MEDICINE INC. news, videos and press releases
For more news please use our advanced search feature.
DISC MEDICINE INC. - More news...
DISC MEDICINE INC. - More news...
- Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
- Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission
- Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
- Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)
- Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025
- Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
- Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting
- Disc Medicine to Participate in Upcoming Investor Conferences
- Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update
- Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.
- Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
- Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval
- Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
- Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week
- Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer
- Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week
- Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer
- Disc Medicine to Participate in Upcoming Investor Conferences
- Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update
- Disc Medicine Announces Underwritten Offering of Common Stock
- Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress
- Disc Medicine to Participate in the Jefferies Global Healthcare Conference
- Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress
- Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference
- Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
- Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
- Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
- Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer
